Abstract
Purpose: Hypertrophic changes in chondrocytes have a potential role in early and late osteoarthritis (OA) progression. RUNX2 is a master regulator of chondrocyte hypertrophy and the RUNX2-activated catabolic factors such as MMP13 and ADAMTS5 are involved in cartilage degradation, so RUNX2 could also be used as a target to alleviate inflammation associated with OA. Thus, inhibition of RUNX2-mediated changes such as chondrocyte hypertrophy in OA joint tissue may be one of the therapeutic targets to slow down the further OA progression.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
